SMMT Stock Cash Flow Statements

Summit Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Summit Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31

cash flows from operating activities:
net income	-565,708,000	-62,913,000	-61,203,000	-56,254,000	-60,385,000	-43,473,000	-36,567,000	-21,268,000	-14,717,000	-542,376,000	-19,229,000	-21,385,000	-16,771,000	-21,397,000	-27,099,000	-19,599,000	-24,416,000	-17,488,000	-13,442,000
adjustments to reconcile net income to net cash from operating activities:
amortization of discount on short-term investments	-1,023,000	-2,966,000	2,350,000	-2,919,000	-1,605,000	-402,000	-208,000	1,185,000
unrealized foreign exchange gain	-239,000	-224,000				9,000		494,000	-394,000	-470,000		1,905,000	1,329,000	1,037,000	972,000	849,000	224,000	-1,719,000
depreciation	37,000	25,000	22,000	20,000	20,000	27,000	30,000	32,000	46,000	90,000	88,000	93,000	99,000	69,000	79,000	81,000	90,000	80,000	35,000
stock-based compensation	478,784,000	11,096,000	11,015,000	19,371,000	11,088,000	9,507,000	8,753,000	705,000	1,875,000	2,775,000	2,658,000	2,798,000	2,496,000	3,996,000	5,620,000	2,644,000	3,672,000	868,000	578,000
acquired in-process research and development expense			0	7,000
change in operating assets and liabilities:
prepaid expenses and other current assets	-1,931,000	1,850,000
other assets	-2,253,000	-1,419,000
accounts payable	17,931,000	356,000	1,529,000	-188,000	-3,030,000	3,704,000	-672,000	2,330,000	297,000	308,000	-2,369,000	-1,042,000	-3,480,000	2,759,000	-1,364,000	-1,019,000	2,754,000	-2,082,000	3,491,000
accrued liabilities	4,841,000	1,611,000		6,096,000	5,952,000	-2,154,000	5,351,000	-200,000	-8,258,000	730,000	-35,000	5,895,000	-246,000	-832,000		1,134,000	1,175,000	2,102,000	-100,000
other current liabilities	704,000	-1,046,000
other non-current liabilities
accrued compensation	2,181,000	-7,588,000	4,042,000	3,066,000	-1,157,000	606,000	1,910,000	-10,000	1,103,000	-3,238,000	4,046,000	648,000	438,000	-3,523,000
operating lease right-of-use assets and lease liabilities	-95,000	25,000	48,000	37,000	-160,000	-92,000
net cash from operating activities	-66,744,000	-61,168,000	-48,673,000	-30,297,000	-33,002,000	-30,134,000	-19,459,000	-14,897,000	-29,273,000	-13,131,000	5,191,000	-8,555,000	-19,217,000	-19,001,000	-9,179,000	-23,565,000	-19,174,000	-20,669,000	-7,971,000
capex	0	-422,000	0	-58,000	-63,000	-4,000	0	-53,000	-20,000	-53,000	0	20,000	-293,000	-361,000	0	0	-151,000	-39,000	0
free cash flows	-66,744,000	-61,590,000	-48,673,000	-30,355,000	-33,065,000	-30,138,000	-19,459,000	-14,950,000	-29,293,000	-13,184,000	5,191,000	-8,535,000	-19,510,000	-19,362,000	-9,179,000	-23,565,000	-19,325,000	-20,708,000	-7,971,000
cash flows from investing activities:
purchases of property and equipment	0	-422,000		-58,000	-63,000	-4,000		-53,000	-20,000	-53,000		20,000	-293,000	-361,000
purchase of short-term investments			-149,488,000	-167,549,000	-270,013,000	-92,982,000	1,000	-112,858,000	-38,170,000	-169,995,000
maturities and sales of short-term investments	150,808,000	160,532,000	232,984,000	73,999,000	69,997,000	112,857,000	60,569,000	109,425,000
net cash from investing activities	150,808,000	160,110,000	83,482,000	-108,615,000	-200,079,000	19,871,000	60,568,000	-3,486,000	207,000	-645,063,000	10,000	20,000	-293,000	-361,000	-120,000	4,000	-151,000	-39,000	-50,000
cash flows from financing activities:
proceeds from the issuance of common stock via private placements, net of offering costs			-101,000
proceeds received related to the exercise of warrants	1,657,000	5,658,000		0
proceeds received related to employee stock awards and purchase plans	565,000	2,019,000
net cash from financing activities	2,222,000	7,677,000	-23,612,000	204,142,000	200,212,000	485,000	6,252,000	229,000	-80,000	80,112,000	520,060,000	74,997,000	0	25,187,000	1,261,000	676,000	20,082,000	55,897,000	50,548,000
effect of exchange rate changes on cash	61,000	38,000		114,000	12,000	-36,000		-170,000	293,000	444,000		-1,826,000	-605,000	-166,000
increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of period	0	105,187,000	0	0	0	71,425,000
cash, cash equivalents and restricted cash at end of period	86,347,000	211,844,000	11,089,000	65,344,000	-32,857,000	61,611,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	86,346,000	211,526,000
restricted cash	1,000	318,000
cash, cash equivalents, and restricted cash	86,347,000	211,844,000
supplemental disclosure of cash flow information:
cash paid for interest on related party promissory notes				0	0	1,501,000		2,917,000	3,488,000	1,306,000
supplemental disclosure of non-cash investing and financing activities:
upfront consideration to akeso for second amendment
leased assets obtained in exchange for operating lease liabilities
unpaid amounts related to purchase of property, plant and equipment
other long-term liabilities		25,000	25,000	24,000
increase in cash and cash equivalents		106,657,000						-18,324,000	-28,853,000	-577,638,000
cash flows used in operating activities:
gain on remeasurement of liabilities
non-cash interest expense							82,000	-63,000	111,000	6,123,000	3,450,000	-88,000	743,000	198,000	-284,000	165,000	212,000	103,000
unrealized foreign currency gain
reclassification of currency translation gain							0	0	0	-419,000
impairment of fixed assets							0	0	0	474,000
amortization of intangible assets											217,000	217,000	232,000	248,000	249,000	256,000	257,000	255,000	423,000
impairment of intangible assets
loss on disposal of assets
changes in operating assets and liabilities:
accounts receivable							0	3,000	6,000	350,000	-1,412,000	1,227,000	705,000	455,000	932,000	-1,366,000	-590,000	-114,000
research and development tax credit receivable			-203,000	260,000	-154,000	632,000	-178,000	3,449,000	47,000	850,000	12,112,000	-1,249,000	-760,000	-1,666,000	5,592,000	-3,753,000	-4,193,000	-3,661,000	-884,000
deferred revenue and other income											276,000	-3,422,000	-1,474,000	-2,658,000
accrued liabilities and other current liabilities
cash flows used in investing activities:
purchase of property and equipment																	-151,000	-39,000
proceeds from sale of property, plant and equipment
payments to akeso for upfront milestone payments and associated direct transaction costs			0				0	0	0	-475,015,000
proceeds from the issuance of common stock under at-the-market offering, net of commissions and offering costs			-4,000
proceeds from the issuance of common stock for rights offering							0	0	0	104,686,000
transaction costs from the issuance of common stock for rights offering
net receipts related to the exercise of warrants
proceeds received related to employee stock purchase plan and exercise of stock options
proceeds from related party promissory notes											520,000,000	0			0
re-payment of related party promissory notes
payments of related party promissory notes issuance costs
effect of exchange rates on cash and cash equivalents																	435,000	588,000	2,620,000
cash paid for interest on related party promissory note															82,000	-82,000
cash paid for income taxes							0	0								0
debt issuance costs in accrued expenses																		38,000
consideration for the issuance of common stock for rights offering used to satisfy a portion of a related party promissory note							0	0	0	395,314,000
deferred transaction costs included in other non-current assets
issuance of common stock pursuant to the akeso license agreement							0	0	0	45,900,000
gain on disposal of assets								11,000
prepaid expenses				-181,000	3,545,000	-2,792,000	2,640,000	1,011,000	-4,896,000	331,000	101,000	3,775,000	-1,451,000	2,682,000	1,280,000	-2,903,000	2,330,000	1,638,000	-1,878,000
other current and long-term assets				-151,000	-275,000	2,531,000	-43,000	-2,455,000	-1,431,000	508,000
proceeds from sale of property and equipment
proceeds from the issuance of common stock for rights offering, net of offering costs
repayment of related party promissory notes								0	0	-24,686,000
offering costs included in accounts payable and accrued expenses
lease assets obtained in exchange for operating lease liabilities				0	0	4,216,000		0								0
unrealized foreign exchange
proceeds from sale of property. plant and equipment							0	0
transaction costs related to the issuance of common stock for rights offering								0	-80,000	-539,000
proceeds from the issuance of common stock via private placement
proceeds received related to employee stock awards					111,000	485,000		229,000	0	651,000		108,000	0	187,000
decrease in cash and cash equivalents					-32,857,000	-9,814,000
in-process research and development expense							0	0	0	520,915,000
other long- term liabilities						1,763,000
transaction costs included in accrued expenses										80,000					0	28,000
unrealized foreign currency (gain) loss
amortization of operating right-of-use assets							575,000	567,000	425,000	285,000	291,000	402,000	260,000	298,000	343,000	295,000
operating lease liabilities							-692,000	-688,000	-464,000	-367,000	-208,000	-297,000	-297,000	-297,000	-325,000	-292,000
supplemental disclosure of cash flow information
cash at beginning of the period								0	0	648,607,000		0	0	71,791,000
cash and cash equivalents at end of the period								-18,324,000	-28,853,000	70,969,000							1,192,000	102,194,000
unrealized foreign exchange loss
other adjustments
proceeds from the issuance of common stock
transaction costs from the issuance of common stock
proceeds from exercise of share options																			596,000
effect of exchange rates on cash and restricted cash
cash at beginning of period
other current assets												1,941,000	-1,013,000	-370,000		-277,000	-354,000	549,000	270,000
payment of related party promissory notes issuance costs
other long-term assets
proceeds from the issuance of common stock for rights-offering
transaction costs related to the issuance of common stock for rights-offering
increase in cash													-20,115,000	5,659,000	-8,457,000
cash at end of the period													-20,115,000	77,450,000
united kingdom
united states
proceeds from related party promissory note														25,000,000			55,000,000	55,000,000
promissory note issuance costs in accrued expenses
gain on recognition of contingent consideration payable
accrued liabilities and accrued compensation
effect of exchange rates on cash
cash at end of period
cash paid (received) for income taxes
intangible asset
option over non-financial assets
loss on disposal of asset
deferred revenue
proceeds from issuance of common stock from rights offering
transaction costs on issuance of common stock from rights offering																-54,000
payments of debt issuance costs																0
proceeds from exercise of stock options																730,000	241,000	897,000
revenue by category:
licensing agreements
cash flows from operating activities
deferred revenue and income																	-354,000	-1,200,000
cash flows from investing activities
purchase of intangible assets
cash flows from financing activities
proceeds from issue of common stock from rights offering
repayment of related party promissory note
increase / (decrease) in cash and cash equivalents																	1,192,000	35,777,000
cash and cash equivalents at beginning of the period																	0	66,417,000
depreciation of operating right-of-use assets																		152,000
lease liabilities																		-152,000	-118,000
(gain) loss on recognition of contingent consideration payable
unrealized foreign exchange (gain) loss
depreciation of operating lease right-of-use assets
impairment of goodwill and intangible assets
deferred income taxes
accounts and other receivables
contingent consideration paid
other liabilities
cash and cash equivalents at beginning of the period / year
cash and cash equivalents at end of the period / year
(gain)/loss on recognition of contingent consideration payable
other (income)/expense
deferred income
investing activities
purchase of property, plant and equipment
financing activities
proceeds from issue of share capital
transaction costs on share capital issued
(decrease) / increase in cash and cash equivalents
cash and cash equivalents at beginning of the year
cash and cash equivalents at end of the year

We provide you with 20 years of cash flow statements for Summit Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Summit Therapeutics stock. Explore the full financial landscape of Summit Therapeutics stock with our expertly curated income statements.

The information provided in this report about Summit Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.